Pacific Biosciences of California, Inc. (PACB)
- Previous Close
1.4700 - Open
1.5100 - Bid 1.3200 x 1300
- Ask 1.4200 x 1300
- Day's Range
1.3500 - 1.5100 - 52 Week Range
1.2500 - 14.5500 - Volume
6,496,765 - Avg. Volume
9,765,237 - Market Cap (intraday)
368.434M - Beta (5Y Monthly) 1.83
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2100 - Earnings Date Apr 30, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.08
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
www.pacb.comRecent News: PACB
Performance Overview: PACB
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PACB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PACB
Valuation Measures
Market Cap
393.89M
Enterprise Value
696.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.86
Price/Book (mrq)
0.56
Enterprise Value/Revenue
3.47
Enterprise Value/EBITDA
-2.51
Financial Highlights
Profitability and Income Statement
Profit Margin
-152.97%
Return on Assets (ttm)
-10.92%
Return on Equity (ttm)
-48.53%
Revenue (ttm)
200.52M
Net Income Avi to Common (ttm)
-306.74M
Diluted EPS (ttm)
-1.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
634.42M
Total Debt/Equity (mrq)
133.17%
Levered Free Cash Flow (ttm)
-306.52M